Led by the duo who brought the first anti-VEGF drug to market, EyeBio aims to develop the next breakthrough eye therapy via a novel tri-specific antibody.
Eyebio, the company launched last year by two ophthalmology drug development veterans, believes it can surpass the benefits of existing anti-VEGF blockbusters with its pipeline of multi-specific agonist antibodies.
Co-founded by former Roche ophthalmology research leader Tony Adamis and ex-CEO of retinal diseases biotech Iveric Bio David...
The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.
More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.
A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.
